Guideline draft of appropriate use of 131I-MIBG for internal radiotherapy of neuroendocrine tumors

Masayuki Nakajo, Keiichiro Yoshinaga, Noboru Oriuchi, Seigo Kinuya, Kunihiko Yokoyama, Toshiro Yamaguchi

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

I3I-MIBG has been used for therapy of unresectable neuroendocrine tumors including malignant pheochromocytomas and neuroblastomas in foreign countries since the '80s when its clinical therapeutic trials were initiated. In Japan, 131I-MIBG for therapy has not been approved by Health and Labor Ministry, however, personally imported 131I-MIBG is now available in limited institutions for therapeutic purpose. This guideline draft was made to provide the information about 131I-MIBG radiotherapy including related side effects for doctors, nurses, patients and their families, to prevent the adverse effects of this therapy and to protect radiation injuries from this tracer. The appendices were also attached concerning practical guidance for attending physicians, patient management and referring physicians for their conveniences.

Original languageEnglish
Pages (from-to)suppl 1-40
JournalKaku igaku. The Japanese journal of nuclear medicine
Volume45
Issue number1
Publication statusPublished - 2008 Feb
Externally publishedYes

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Guideline draft of appropriate use of 131I-MIBG for internal radiotherapy of neuroendocrine tumors'. Together they form a unique fingerprint.

Cite this